The Advisory Board Co. (ABCO) Downgraded by Bank of America Corp.
Other equities analysts have also recently issued research reports about the stock. Barclays PLC boosted their price objective on shares of The Advisory Board from $44.00 to $50.00 and gave the company an overweight rating in a research report on Friday, September 30th. Canaccord Genuity set a $50.00 price objective on shares of The Advisory Board and gave the company a buy rating in a research report on Wednesday, September 28th. Zacks Investment Research cut shares of The Advisory Board from a hold rating to a sell rating in a research report on Monday, October 17th. William Blair restated an outperform rating on shares of The Advisory Board in a research report on Tuesday, September 27th. Finally, Credit Suisse Group AG restated a buy rating and issued a $50.00 price objective on shares of The Advisory Board in a research report on Friday, September 16th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the stock. The Advisory Board currently has an average rating of Buy and a consensus price target of $43.25.
The Advisory Board (NASDAQ:ABCO) opened at 34.35 on Monday. The Advisory Board has a 12 month low of $18.87 and a 12 month high of $54.83. The company’s market cap is $1.38 billion. The company has a 50-day moving average of $41.57 and a 200 day moving average of $38.34.
The Advisory Board (NASDAQ:ABCO) last issued its earnings results on Tuesday, November 1st. The company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by $0.12. The business earned $200.50 million during the quarter, compared to analysts’ expectations of $203.35 million. The Advisory Board had a positive return on equity of 11.49% and a negative net margin of 5.77%. The Advisory Board’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.33 EPS. On average, equities analysts forecast that The Advisory Board will post $1.83 earnings per share for the current fiscal year.
In other news, insider Cormac F. Miller sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $43.04, for a total value of $64,560.00. Following the transaction, the insider now owns 18,987 shares in the company, valued at $817,200.48. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Evan R. Farber sold 2,924 shares of the company’s stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $40.95, for a total transaction of $119,737.80. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of ABCO. Rail Splitter Capital Management LLC purchased a new position in shares of The Advisory Board during the second quarter valued at about $4,187,000. Ngam Advisors L.P. bought a new position in The Advisory Board during the second quarter valued at $423,000. Rice Hall James & Associates LLC boosted its position in The Advisory Board by 1.5% in the second quarter. Rice Hall James & Associates LLC now owns 360,064 shares of the company’s stock valued at $12,743,000 after buying an additional 5,322 shares during the last quarter. Confluence Investment Management LLC boosted its position in The Advisory Board by 1,192.7% in the second quarter. Confluence Investment Management LLC now owns 614,292 shares of the company’s stock valued at $21,740,000 after buying an additional 566,772 shares during the last quarter. Finally, Stoneridge Investment Partners LLC bought a new position in The Advisory Board during the second quarter valued at $2,287,000.
The Advisory Board Company Profile
The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues, including physician alignment and engagement, network management and growth strategy, value-based care and population health, revenue cycle, clinical operations and supply chain.
Receive News & Stock Ratings for The Advisory Board Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Advisory Board Co. and related stocks with our FREE daily email newsletter.